Axsome Therapeutics (NASDAQ: AXSM ) has been on an evolution moving from being a development-stage company into a neuroscience company. Three of its drugs are now being marketed and has a rich late-stage pipeline. Q3 2025 earningsGamu Dave Innocent Pasi is a seasoned financial professional and writer, bringing a wealth of experience from his prior roles as a financial analyst and in investment research. With a strong background in analyzing financial statements, capital markets, and the macro-economy, Gamu ...

Axsome Therapeutics (NASDAQ: AXSM ) has been on an evolution moving from being a development-stage company into a neuroscience company. Three of its drugs are now being marketed and has a rich late-stage pipeline. Q3 2025 earningsGamu Dave Innocent Pasi is a seasoned financial professional and writer, bringing a wealth of experience from his prior roles as a financial analyst and in investment research. With a strong background in analyzing financial statements, capital markets, and the macro-economy, Gamu ...

PresentationDiane Smith-Gander Good morning, everyone. My name is Diane Smith-Gander, and I'm the Chair of Perenti. It's now 10:30 a.m. Perth time, and I welcome all shareholders to the company's 2025 Annual General Meeting, both here in person and online through the virtual meeting platform provided by our share registry, MUFG Corporate Markets Limited. If we experience any technical issues today, a short recess or an adjournment may be required, depending on the number of shareholders affected. If this o ...

NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is recognizing Mental Illness Awareness Week (MIAW) alongside the national mental health advocacy community including the National Alliance on Mental Illness (NAMI). This year’s theme for MIAW is “Building Community: Supporting Mental Well-being Together,” to highlight the importance of meaningful co ...

NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the third quarter of 2025 on Monday, November 3, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the liv ...

Axsome Therapeutics Inc. (NASDAQ:AXSM) ranks among the best biotech stocks to buy. Following a recent discussion with the senior management at Axsome Therapeutics Inc. (NASDAQ:AXSM), Piper Sandler reiterated its Overweight rating on the company and set a price target of $148 on its shares. The firm learned about Axsome’s commercial support methods for Auvelity in major depressive disorder (MDD) and its possible extension into agitation associated with Alzheimer’s disease (AD-agitation). With management a ...

The legendary zoologist and animal rights activist Jane Goodall passed away Wednesday, according to her institute. She was 91.Goodall made ground-breaking discoveries about chimpanzees, including their ability to make and use tools and their capacity for empathy. As one of the most well-known scientists of the 20th century, her career paved the way for more women to enter what had been largely male-dominated spaces.At the Forbes Sustainability Summit last week, Goodall spoke about the need for corporate lea ...

Axsome Therapeutics has three drugs on the market and five in the pipeline, with the potential to help some 150 million Americans suffering from brain disorders.When Herriot Tabuteau started a drug development company in 2012, he decided to do so differently. First, he’d focus on brain disorders, treatments for which are notoriously difficult to develop and whose efficacy can be hard to prove. And he’d be both CEO and the scientific founder, bringing to bear his dec­ades of experience investing in biotech s ...

Key Takeaways Axsome's Auvelity posted $215.9M in H1 2025 sales, which increased 82.3% year over year.AXSM plans to file an sNDA for Auvelity in the AD agitation later in the third quarter of 2025.Sunosi sales rose 25.6% in H1 2025, while Symbravo was launched in June after FDA approval.Axsome Therapeutics’ (AXSM) lead drug, Auvelity (AXS-05), approved for treating major depressive disorder, has witnessed strong sales uptake since its approval and launch. Auvelity, the first approved product in Axsome’s com ...

Both should have significant catalysts by the end of the decade.Every investor wants to outperform the market, but it's a challenging feat to achieve. That's why few manage to do it consistently over long periods. What's the best approach to take? Day trading is probably not it. Some research suggests that the overwhelming majority of day traders not only fail to beat the market, but actually lose money over the long run.A better strategy is to invest in quality stocks with attractive long-term prospects, a ...